Home / Indicators / IFRS net income growth vs Novel active substance launches IFRS net income growth vs Novel active substance launches IFRS net income growth and Novel active substance launches worldwide, compared over time.
Change the pair
Compare different indicators
The series
Over time Global, spaced by time
. Different units, drawn on separate scales and clipped to the years both
series publish — earlier history stays on each indicator's own page.
Read the values, not the heights.
IFRS net income growth
Unit: % · 2 observations
Line chart IFRS net income growth IFRS net income growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91.3% to -66.3%. Latest value -91.3% (Q2 2026).
%
-100
-80
-60
-40
-20
0
2004
2008
2012
2016
2020
2024
-66%
-91%
IFRS net income growth IFRS net income growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91.3% to -66.3%. Latest value -91.3% (Q2 2026).
%
-120
-90
-60
-30
0
2004
2008
2012
2016
2020
2024
-66%
-91%
IFRS net income growth IFRS net income growth. 2 observations from Q1 2026 to Q2 2026, ranging from -91.3% to -66.3%. Latest value -91.3% (Q2 2026).
%
-120
-90
-60
-30
0
2004
2008
2012
2016
2020
2024
-66%
-91%
View the underlying data Novel active substance launches
Unit: count · 2 observations
Line chart Novel active substance launches Novel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025).
0
200
400
600
800
1,000
2004
2008
2012
2016
2020
2024
942
79
Novel active substance launches Novel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025).
0
300
600
900
1,200
2004
2008
2012
2016
2020
2024
942
79
Novel active substance launches Novel active substance launches. 2 observations from 2004–2023 to 2025, ranging from 79 to 942. Latest value 79 (2025).
0
300
600
900
1,200
2004
2008
2012
2016
2020
2024
942
79
View the underlying data Provenance
Where these numbers come from Percentage change in IFRS net income compared to the corresponding period of the previous year.
2 observations in Global · source
organisations: Sanofi
Total number of novel active substances launched.
2 observations in Global · source
organisations: IFPMA, IQVIA
Data published under CC BY 4.0 .
Series A as JSON · Series B as JSON